



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 2-1000-07-1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 4

Street 101 City 4 Altarkey Block Number 510107

U.S. PATENT DOCUMENTS

RECEIVED

~~MAR - 6 2006~~

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
/SP/	10	EP 0320308 B1	11/3/1993	Backman		X
/SP/	11	WO 89/09284	10/5/1989	Walder		X
/SP/	12	GB 2 202328 A	9/21/1988	Soderlund		X
/SP/	13	WO 88/10315	12/29/1988	Gingeras		X
/SP/	14	EP 0329822 B1	6/8/1994	Davey		X
/SP/	15	WO 89/06700	7/27/89	Miller		X

**Examiner
Signature**

/Steven Pohnert/ (03/24/2007) Date Considered

Date

***EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.**

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

4

Complete If Known

Application Number	10/527,831
Filing Date	1/9/2006
First Named Inventor	North
Art Unit	1044
Examiner Name	

RECEIVED

MAR 6 2006

TECH CENTER 1600/2500

Attorney Docket Number 316187

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/SP/	16	BLANCHARD, ANDREW, et al., "The Structure and function of a-actinin," Journal of Muscle Research and Cell Motility 10, 280-289 (1989)	
/SP/	17	BEGGS, Alan H., et al., "Cloning and Characterization of Two Human Skeletal Muscle a-Actinin Genes Located on Chromosomes 1 and 11" The Journal of Biological Chemistry, Vol. 267, No. 13, Issue of May 5, pp 9281-9288, 1992	
/SP/	18	NAVE, RUDIGER, et al., "Interaction of a-actinin and nebulin In vitro," Elsevier Science Publishers, Vol. 269, No. 1, 163-168, August 1990	
/SP/	19	PAPA, IRIS, et al., "Alpha actinin-CapZ, an anchoring complex for thin filaments In Z-line," Journal of Muscle Research and Cell Motility 20, pgs. 187-197, 1999 Kluwer Academic Publishers	
/SP/	20	SALMIKANGAS, PAULA, et al., "Myotilin, a novel sarcomeric protein with two Ig-like domains, is encoded by a candidate gene for limb-girdle muscular dystrophy," Human Molecular Genetics, 1999, Vol. 8, No. 7, pgs. 1329-1336 1999 Oxford University Press	
/SP/	21	BELLIN, Robert M., et al., "Molecular characteristics and Interactions of the Intermediate Filament Protein Synemin," The Journal of Biological Chemistry, Vol. 274, No. 41, Issue of October 8, pgs. 29493-29499	
/SP/	22	MCGREGOR, ALISTAIR, "Identification of the Vinculin-binding Site in the Cytoskeletal Protein a-actinin" Biochem (1994) 301, pgs. 225-233 (Printed In Great Britain)	
/SP/	23	HANCE, Jacqueline, "a-Actinin-2 Is a New Component of the Dystrophin-Glycoprotein Complex" Archives of Biochemistry and Biophysics, Vol. 365, No. 2, May 15, pgs. 216-222, 1999	
/SP/	24	OTEY, Carol A., et al., "Mapping of the a-Actinin Binding Site within the B1 Integrin Cytoplasmic Domain," The Journal of Biological Chemistry, Vol. 268, No. 28, Issue of October 5, pgs. 21193-21197	
/SP/	25	FUKAMI, et al., "a-Actinin and Vinculin Are PIP2-binding Proteins Involved In Signalling by Tyrosine Kinase" The Journal of Biological Chemistry, Vol. 269, No. 2, Issue of January 14, pgs. 1518-1522, 1994	
/SP/	26	SHIBASAKI, Futoshi, et al., "Phosphatidylinositol 3-kinase binds to a-actinin through the p85 subunit" Biochem Journal (1994) 302, pgs. 551-557 (Printed In Great Britain)	


Examiner Signature	/Steven Pohnert/ (03/24/2006)	Date
--------------------	-------------------------------	------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



RECEIVED

Substitute for form 1449B (2001)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

of

4

Complete If Known

Application Number	10/527,831	MAR - 6 2006
Filing Date	1/9/2006	
First Named Inventor	North	
Art Unit	1641	
Examiner Name	TECH CENTER 600/2900	
Attorney Docket Number	316187	

Attorney Docket Number

316187

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/SP/	27	POMIES, PASCAL, et al., "CRP1, a LIM Domain Protein Implicated in Muscle Differentiation, Interacts with a-Actinin" The Journal of Cell Biology, Volume 139, Number 1, October 6, 1997, pgs. 157-168	
/SP/	28	POMIES, PASCAL, et al., "Purification and Characterization of an a-Actinin-Binding PDZ-LIM Protein that is Up-regulated during Muscle Differentiation" The Journal of Biological Chemistry, 1999 the The American Society for Biochemistry and Molecular Biology, Inc., Vol. 274, No. 41, Issue of October 8, 1999, pgs. 29242-29250	
/SP/	29	NORTH, KATHRYN, et al., "A common nonsense mutation results in a-actinin-3 deficiency in the general population" 1999 Nature America Inc., Vol. 21, April 1999, pgs. 353-354	
/SP/	30	NOWAK, Martin A, et al., "Evolution of genetic redundancy" Letters to Nature Vol. 388 10 July 1997, pgs. 167-171	
/SP/	31	CHAN, YIU-MO, et al., "Human Skeletal Muscle-Specific a-Actinin-2 and -3 Isoforms Form Homodimers and Heterodimers in Vitro and In Vivo" Biochemical and Biophysical Research Communications 248, 1998 Article No. RC 988920, pgs. 134-139	
/SP/	32	RIEDER, MARK J., "Sequence variation in the Human Angiotensin Converting Enzyme" Nature Genetics, Vol. 22, May 1999, pgs. 59-62	
/SP/	33	GAYAGAY, George, et al., "Elite Endurance Athletes and the ACE I allele – the role of Genes in Athletic Performance" Hum Genet (1998) 103 pgs. 48-50	
/SP/	34	MONTGOMERY, H. E., et al. "Human Gene for Physical Performance" scientific correspondence Nature Macmillan Publishers Ltd 1998 Vol. 393 May 21, 1998, pgs. 221-222	
/SP/	35	MYERSON, SAUL, et al. "Human Angiotensin I-converting enzyme gene and Endurance Performance" The American Physiological Society 1999 8750-7587/99, pgs. 1313-1316	
/SP/	36	NAZAROV, Igor B., et al. "The angiotensin Converting Enzyme I/D polymorphism in Russian athletes" European Journal of Human Genetics (2001) 9, pgs. 797-801	
/SP/	37	WOODS, DAVID, et al., "Elite Swimmers and the D allele of the ACE I/D Polymorphism" Hum Genet (2001) 108, pgs 230-232	

Examiner Signature	/Steven Pohnert/ (03/24/2007)	Date Considered	
--------------------	-------------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

MAR 0 2006

PTO/SB/08B(07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

4

of

4

Complete If Known

Application Number	10/527,831	MAR - 2006 TECH CENTER 1600/2900
Filing Date	1/9/2006	
First Named Inventor	North	
Art Unit	1641	
Examiner Name		

Attorney Docket Number

316187

RECEIVED

2006

1600/2900

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/SP/	38	MELTZOFF, A., "Rational Imitation in Preverbal Infants" Nature, Vol. 415, 14 February 2002, pgs. 755-756	
/SP/	39	RANKINEN, TUOMO, et al., "The Human Gene Map for Performance and Health-related Fitness Phenotypes: the 2001 update" MSSE Special Report, 0195-9131/02/3408-1219, 2002 by the American College of Sports Medicine	
/SP/	40	PERUSSE, LOUIS, et al., "The Human Gene Map for Performance and Health-related Fitness Phenotypes: The 2002 Update," Medicine & Science in Sports & Exercise, the American College of Sports Medicine 0195-9131/03/3508 pgs. 1248-1264	
/SP/	41	MILLS, MICHELLE, et al., "Differential expression of the actin-binding proteins, a-actinin-2 and -3, in different species: implications for the evolution of functional redundancy" Human Molecular Genetics, Vol. 10, No. 13, pgs 1335-1346	
/SP/	42	EIZEMA, KARIN, et al., "Differential Expression of Equine Myosin Heavy-chain mRNA and Protein Isoforms in a Limb Muscle" Vol. 51(9): The Journal of Histochemistry & Cytochemistry, 2003, pgs. 1207-1216	
/SP/	43	WALKER, G. TERRANCE, et al., "Isothermal In vitro amplification of DNA by a Restriction enzyme/DNA Polymerase System" Vol. 89, pgs. 392-396, January 1992 Applied Biological Sciences, pgs. 392-396	
/SP/	44	KWOH, D. Y., et al., "Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format" Biochemistry, Proc. Natl. Acad. Sci. USA, Vol. 86, pgs. 1173-1177, February 1989	
/SP/	45	OHARA, OSAMU, et al., "One-sided Polymerase Chain Reaction: The amplification of cDNA" Pro. Natl. Acad. Sci. USA, Biochemistry, Vol. 86, pgs. 5673-5677, August 1989	
/SP/	46	NORTH, KATHRYN N., et al., "Deficiency of a Skeletal Muscle Isoform of a-Actinin (a-Actinin-3) in Merosin-Positive Congenital Muscular Dystrophy" Neuromusc. Disord., Vol. 6, No. 4, pgs. 229-235, 1996	
/SP/	47	FRIDEN, J., et al., "Eccentric Exercise-Induced Injuries to Contractile and Cytoskeletal Muscle Fibre components" Acta Physiol Scand 2001, 171, Scandinavian Physiological Society, pgs. 321-326	

Examiner Signature	/Steven Pohnert/ (03/24/2007)	Date Considered	
--------------------	-------------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10527831
	Filing Date	2006-01-09
	First Named Inventor	North
	Art Unit	1644 → 1634 John Neff
	Attorney Docket Number	59195-316187

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.
 Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Richard A. Nakashima/	Date (YYYY-MM-DD)	2007-01-08
Name/Print	Richard A. Nakashima	Registration Number	42,023

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

10/527831
Rec'd PCT/PTO 09 JAN 2006
#4

IN THE UNITED STATES DESIGNATED OFFICE (DO/US)


In Re the Application of:)
NORTH, Kathryn Nance)
Int'l. Serial No.: PCT/AU2003/001202)
Int'l. Filing Date: September 15, 2003)
Priority Date: September 14, 2002)
U.S. Serial No.: 10/527,831)
For: "ACTN3 GENOTYPE SCREEN FOR)
ATHLETIC PERFORMANCE")
Atty. File No.: 59195-316187)

INFORMATION DISCLOSURE
STATEMENT

"EXPRESS MAIL" MAILING LABEL NUMBER: EV572273168US
DATE OF DEPOSIT: 1-9-06

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE
"EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE
UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS
ADDRESSED TO COMMISSIONER FOR PATENTS, BOXPCT, P.O.
BOX 1450, ALEXANDRIA, VA 22313-1450.

TYPED OR PRINTED NAME: JANICE MESSER

SIGNATURE: 

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The references cited on attached Form PTO-1449 are being called to the attention of the Examiner.

- Copies of the cited non-patent and/or foreign references are enclosed herewith.
- Copies of the cited U.S. patents and/or patent applications are enclosed herewith.
- Copies of the cited U.S. patents/patent application publications are not enclosed in accordance with the waivers dated July 11, 2003 and October 19, 2004, whereby patent applications filed, regardless of the filing date, need not submit copies of U.S. patents and U.S. patent application publications.
- Copies of the cited references are not enclosed, in accordance with 37 C.F.R. 1.98(d), because the references were cited by or submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____ filed _____, which is relied upon for an earlier filing date under 35 U.S.C. § 120.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete If Known

Application Number	10/527,831
Filing Date	March 15, 2005
First Named Inventor	Kathryn Nance North
Art Unit	
Examiner Name	
Sheet	1
of	1
Attorney Docket Number	59195-316187

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code <small>(If known)</small>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² ; Number ³ ; Kind Code ⁴ <small>(If known)</small>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		PCT -				
		-				
		-				
		-				
		-				
		-				

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner Initials*	Cite No. ¹	
/SP/		"Deficiency of α -Actinin-3 (ACTN3) Occurs in Different Forms of Muscular Dystrophy" by Vainzof et al., <i>Neuropediatrics</i> 28 (1997), 223-228
/SP/		"ACTN3 Genotype is Associated with Human Elite Athletic Performance" by Yang et al., <i>American Journal of Human Genetics</i> , 73: 627-631, 2003
/SP/		"Differential Expression of the Actin-Binding Proteins, α -actinin-2 and -3, in Different Species: Implications for the Evolution of Functional Redundancy" by Mills, et al., <i>Human Molecular Genetics</i> , 2001, Vol. 10, No. 13, 1335-1346
/SP/		"Deficiency of Muscle α -Actinin-3 is Compatible with High Muscle Performance" BY Zanoteli et al., <i>Journal of Molecular Neuroscience</i> , Vol. 20, 2003, pp. 39-42.
/SP/		"A Common Nonsense Mutation Results in α -Actinin-3 Deficiency in the General Population" by North et al., <i>Nature Genetics</i> , Vol. 21, April 1999, pp. 353-354

Examiner Signature	/Steven Pohnert/ (04/06/2007)	Date Considered
--------------------	-------------------------------	-----------------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Not for submission under 37 CFR 1.99)</small>	Application Number		10527831
	Filing Date		2006-01-09
	First Named Inventor		North
	Art Unit		1634
	Examiner Name		pohnert
	Attorney Docket Number		59195-316187

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
--------------------	---------	---	----------------

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10527831
	Filing Date	2006-01-09
	First Named Inventor	North
	Art Unit	1041-1634
	Examiner Name	Pohner P
	Attorney Docket Number	59195-316187

/SP/	1	NAZAROV, IGOR B., et al., "The angiotensin converting enzyme I/D polymorphism in Russian athletes" European Journal of Human Genetics (2001) 9, 797-801 XP-002404827	<input type="checkbox"/>
------	---	--	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Steven Pohnert/ (03/24/2007)	Date Considered	
--------------------	-------------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 801.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

Notice of References Cited		Application/Control No.	Applicant(s)/Patent Under Reexamination	
		10/527,831	NORTH, KATHRYN NANCE	
		Examiner	Art Unit	Page 1 of 3
		Steven C. Pohnert	1634	

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S			" "		
	T			" "		

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Mills et al, Human Molecular Genetics (2001) Volume 10, pages 1335-1346
	V	genecards.org/cgi-bin/cardisp.pl?gene=ACTN3&search=actn3&suff=txt, pages 1-11, 3/24/2007
	W	Yang, et al, Med. Sci. Sport and Exercise (2005) volume 37, s42
	X	Moran et al, European Journal of Human Genetics (2007) volume 15, pages 88-93

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.